News Image

iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right

Provided By GlobeNewswire

Last update: Jul 21, 2025

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (“Concentra”) will acquire iTeos for $10.047 in cash per share of iTeos common stock par value $0.001 per share (“iTeos Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of iTeos in excess of $475 million; and (ii) 80% of any net proceeds received from any disposition of certain of iTeos’ product candidates that occurs within six months following the closing (such cash and CVR consideration, the “Offer Consideration”).

Read more at globenewswire.com

ITEOS THERAPEUTICS INC

NASDAQ:ITOS (8/28/2025, 8:19:13 PM)

After market: 10.17 +0.02 (+0.2%)

10.15

+0.02 (+0.2%)



Find more stocks in the Stock Screener

Follow ChartMill for more